
|Videos|September 13, 2017
- Non-Small Cell Lung Cancer
- Volume 1
- Issue 1
Dr. Langer Discusses Ongoing Clinical Trials for Patients With Non-Driver NSCLC
Corey J. Langer, MD, Perelman Center for Advanced Medicine; Hospital of the University of Pennsylvania, discusses ongoing clinical trials for patients with non-driver non-small cell lung cancer (NSCLC).
Advertisement
Articles in this issue
over 8 years ago
Current Treatment Strategies in Nonbiomarker Nonsquamous NSCLCover 8 years ago
Emerging Treatment Strategies in Nonsquamous NSCLCAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5







































